Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | MARK3 | P27448 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.37 |
| ▸ | GALR3 | O60755 | 1/20 | 0.35 |
| ▸ | STK4 | Q13043 | 1/20 | 0.35 |
| ▸ | STK3 | Q13188 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8856393 | 0.84 | CHEK1 (0.47) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL2316376 | 0.77 | CHEK1 (0.42) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL31029494 | 0.77 | LRRK2 (0.39) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL18985531 | 0.77 | LRRK2 (0.39) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL18519961 | 0.76 | CHEK1 (0.41) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL41301 | 0.75 | — | — | |
| SCHEMBL5243561 | 0.75 | EGFR (0.46) | GALR3ALDH1A1 | |
| SCHEMBL22943642 | 0.74 | LRRK2 (0.37) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL5248227 | 0.74 | EGFR (0.38) | HTTCYP1A2MAPK1CYP2D6LMNA | |
| SCHEMBL8856366 | 0.71 | CHEK1 (0.38) | CHEK1AURKALRRK2PDPK1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| WO-2024049929-A2 | PANNEXIN-1 MODULATORS AND METHODS OF TREATING DISORDERS IN WHICH PANNEXIN-1 IS IMPLICATED | PANNEX THERAPEUTICS INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| US-20170369492-A1 | 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE | TAKEDA PHARMACEUTICALS CO (JP) | 2017-12-28 | — | — | US | disclosed |
| US-20170369492-A1 | 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE | TAKEDA PHARMACEUTICALS CO (JP) | 2017-12-28 | — | — | US | disclosed |
| WO-2015198046-A1 | 1,3-SUBSTITUTED 2-AMINOINDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY AND INFLAMMATORY BOWEL DISEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-30 | — | — | WO | disclosed |
| US-5656634-A | N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) | PFIZER INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5397781-A | Pyrimidine derivatives | MOCHIDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-03-14 | — | — | US | disclosed |
| US-5362878-A | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) | PFIZER INC. (US) | 1994-11-08 | — | — | US | disclosed |
| EP-0609960-A1 | New N-heteroarylamide derivatives as inhibitors of acyl coenzyme A: cholestrol acyl transferase | PFIZER INC. (US) | 1994-08-10 | — | — | EP | disclosed |
| EP-0561175-A1 | Pyrimidine derivatives and pharmaceutical compostions containing them | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-22 | — | — | EP | disclosed |
| CN-1050183-A | New N-aryl and N-heteroaryl amide and urea derivatives as acyl-coenzyme a cholesterol acyltransferase (ACAT) inhibitor | PFIZER (US) | 1991-03-27 | — | — | CN | disclosed |
| EP-0418071-A2 | New N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase | PFIZER INC. (US) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369492-A1 | 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE | GPR119, IDO1, IDO2 | HTT 3484/4885CHEK1 4792/4885AURKA 4718/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | HTT 2514/4885CHEK1 463/4885AURKA 1680/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | HTT 2514/4885CHEK1 463/4885AURKA 1680/4885 |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | HTT 2514/4885CHEK1 463/4885AURKA 1680/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | HTT 2514/4885CHEK1 463/4885AURKA 1680/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | HTT 2514/4885CHEK1 463/4885AURKA 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.